At most institutions, “bench-to-bedside” describes a direction. At St. Jude, it describes a system.
Clinical problems drive laboratory questions. Laboratory discoveries return to the clinic as more precise, less toxic therapies. Data from patients informs the next generation of research. The cycle is intentional, and the infrastructure to sustain it has been built over decades.
Research as the foundation
Pediatric diseases are not smaller versions of adult diseases. The biology is distinct and the therapies children need must be developed from the ground up, not borrowed from research designed for adult populations.
Across 24 academic departments and more than more than 150 fundamental and translational research labs, St. Jude scientists investigate mechanisms of fundamental biology and the foundations of catastrophic pediatric diseases — from cancer to sickle cell disease to neurological disorders — anchored in unmet clinical need and guided by the questions that emerge from caring for patients.
Our research environment supports:
- Basic and translational science rooted in pediatric disease biology
- Cross-disciplinary collaboration across departments and labs
- Technology development designed to accelerate discovery
- Intentional movement of findings toward clinical application
55% of recurrent mutations found in pediatric cancers are not present in adult cancers. This is one illustration of why St. Jude research is built around the specific biology of childhood disease.
From discovery to development
A promising discovery is not a therapy. The distance between biological insight and clinical application is where most potential treatments fail, and where St. Jude has invested deliberately to succeed.
The translational path includes:
- Scientific validation and replication
- Preclinical evaluation and optimization
- Biomarker and pharmacology analysis
- Clinical trial planning and regulatory preparation
Infrastructure as the accelerator
St. Jude shared resources span genomics, proteomics, metabolomics, spatial omics, imaging, biostatistics and GMP manufacturing. They are designed to expand what individual research groups can do and shorten the distance between idea and trial.
The GMP advantage
The Children’s GMP, LLC at St. Jude manufactures gene and cell therapy products under federal standards, giving the institution the ability to develop treatments that may not attract initial pharmaceutical investment.
Clinical integration
At St. Jude, research and care run in both directions. Clinicians contribute to research while delivering care. Scientists design studies around questions that emerge from the clinic. Every patient encounter has the potential to inform the next generation of treatment.
This integrated model supports:
- Evaluation of research informed treatment approaches
- Collaboration between laboratory and clinical investigators
- Development of targeted therapies informed by disease biology
- Ongoing alignment between patient care priorities and research strategy
Beyond cures
The survivorship programs at St. Jude translate discoveries into strategies that reduce toxicity, address late effects and improve quality of life, protecting children long after treatment ends.
Gene therapy in practice
St. Jude gene therapy programs span blood diseases, immune disorders and inherited conditions, and move from model systems testing through clinical trial preparation. All of this is supported by the institution’s own manufacturing infrastructure.
Global and institutional impact
The bench-to-bedside system at St. Jude is global by design. Discoveries made here are meant to reach children everywhere, and that requires more than sharing findings. It requires building the systems capable of delivering them.
How St. Jude extends bench-to-bedside globally:
- Global standards of care – Research in genomics, risk stratification and treatment optimization is shared openly and designed to influence how pediatric diseases are diagnosed and treated across varied clinical environments worldwide.
- Infrastructure and knowledge – Through St. Jude Global, the institution strengthens diagnostic capability, workforce training, pathology, pharmacy and clinical operations at partner hospitals, because translation is incomplete without capacity.
- Open-access data and precision medicine – Initiatives like St. Jude Cloud and the Pediatric Cancer Genome Project make genomic data and analytical tools available to researchers and clinicians worldwide, enabling participation in precision medicine that might otherwise be out of reach.
- Bidirectional science – International collaborators contribute patient populations, clinical insight, epidemiological perspectives and implementation expertise that strengthen the research done at St. Jude.
A discovery made in a St. Jude laboratory, developed through its translational infrastructure, tested in its clinics and refined through its survivorship programs ultimately reaches children who need it most, wherever they are. That is the full expression of bench-to-bedside.
More to discover
-
St. Jude Children's Research Hospital
A leading children’s hospital, St. Jude treats the toughest childhood cancers and pediatric diseases. Learn about patient referrals, and donate so families never receive a bill for treatment, travel, housing or food.
-
St. Jude Children's Research Hospital
A leading children’s hospital, St. Jude treats the toughest childhood cancers and pediatric diseases. Learn about patient referrals, and donate so families never receive a bill for treatment, travel, housing or food.
-
St. Jude Children's Research Hospital
A leading children’s hospital, St. Jude treats the toughest childhood cancers and pediatric diseases. Learn about patient referrals, and donate so families never receive a bill for treatment, travel, housing or food.
